TRC120038, a novel dual AT 1/ET A receptor blocker for control of hypertension, diabetic nephropathy, and cardiomyopathy in ob-ZSF1 Rats

International Journal of Hypertension

Volumn 2011, Issue , 2011, Pages

  Mohanan, Anookh ^a   Gupta, Ram ^a   Dubey, Amita ^a   Jagtap, Vikrant ^a   Mandhare, Appaji ^a   Gupta, Ramesh C ^a   Chauthaiwale, Vijay ^a   Dutt, Chaitanya ^a  

^a Torrent Pharmaceuticals Ltd   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; CANDESARTAN HEXETIL; N (4,5 DIMETHYL 1,2 OXAZOL 3 YL) 3 [4 [[4,6 DIMETHYL 3 (THIOPHEN 1 YL) 1H PYRAZOLO[4,3 C]PYRIDIN 1 YL]METHYL] 2 (ETHOXYMETHYL)PHENYL] 5 METHYLTHIOPHENE 2 SULFONAMIDE; PLACEBO; TRC 120038; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CARDIOMYOPATHY; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE CONTROL; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG STRUCTURE; HEART FAILURE; HEART FUNCTION; HEART PROTECTION; HISTOPATHOLOGY; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL PROTECTION; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 84867583095     PISSN: 20900384     EISSN: 20900392     Source Type: Journal    
DOI: 10.4061/2011/751513     Document Type: Article

References (73)

1. Chobanian A. V., Bakris G. L., Black H. R., Cushman W. C., Green L. A., Izzo J. L., Jones D. W., Materson B. J., Oparil S., Wright J. T., Roccella E. J., The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. Journal of the American Medical Association 2003 289 19 2560 2572 2-s2.0-0038460302 10.1001/jama.289.19.2560 (Pubitemid 37430158)
2. Roger V. L., Go A. S., Lloyd-Jones D. M., Adams R. J., Berry J. D., Brown T. M., Carnethon M. R., Dai S., de Simone G., Ford E. S., Fox C. S., Fullerton H. J., Gillespie C., Greenlund K. J., Hailpern S. M., Heit J. A., Ho P. M., Howard V. J., Kissela B. M., Kittner S. J., Lackland D. T., Lichtman J. H., Lisabeth L. D., Makuc D. M., Marcus G. M., Marelli A., Matchar D. B., McDermott M. M., Meigs J. B., Moy C. S., Mozaffarian D., Mussolino M. E., Nichol G., Paynter N. P., Rosamond W. D., Sorlie P. D., Stafford R. S., Turan T. N., Turner M. B., Wong N. D., Wylie-Rosett J., Heart disease and stroke statistics2011 update: a report from the American Heart Association. Circulation 2011 123 4 e18 e209 2-s2.0-78650046021 10.1161/CIR.0b013e3182009701
3. Persell S. D., spersell@nmff.org Prevalence of resistant hypertension in the United States, 20032008. Hypertension 2011 57 6 1076 1080 10.1161/HYPERTENSIONAHA.111.170308
4. Epstein B. J., Efficacy and safety of darusentan: a novel endothelin receptor antagonist. Annals of Pharmacotherapy 2008 42 7-8 1060 1069 2-s2.0-48249109076 10.1345/aph.1L024
5. Rodgers A., MacMahon S., Yee T., Clark T., Blood pressure, cholesterol, and stroke in eastern Asia. Lancet 1998 352 9143 1801 1807 (Pubitemid 28550068)
6. Arauz-Pacheo C., Parrott M. A., Raskin P., Treatment of hypertension in adults with diabetes. Diabetes Care 2003 26 1 S80 S82 2-s2.0-0037898667 (Pubitemid 36928963)
7. National Kidney Foundation Guideline, K/DOQI clinical practice guidelines for chronic kidney disease: kidney disease outcome quality initiative. American Journal of Kidney Diseases 2002 39 S1 S246
8. Ergul S., Parish D. C., Puett D., Ergul A., Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension 1996 28 4 652 655 2-s2.0-0029797408 (Pubitemid 26327964)
9. Laragh J. H., Case D. B., Atlas A., Sealey J. E., Captopril compared with other antirenin system agents in hypertensive patients: its triphasic effect on blood pressure and its use to identify and treat the renin factor. Hypertension 1980 2 4 586 593 2-s2.0-0019166090 (Pubitemid 11224379)
10. Weber M. A., Black H., Bakris G., Krum H., Linas S., Weiss R., Linseman J. V., Wiens B. L., Warren M. S., Lindholm L. H., A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. The Lancet 2009 374 9699 1423 1431 2-s2.0-70350133404 10.1016/S0140-6736(09)61500-2
11. Krum H., Katz S. D., Effect of Endothelin-1 on exercise-induced vasodilation in normal subjects and in patients with heart failure. American Journal of Cardiology 1998 81 3 355 358 2-s2.0-0032005172 10.1016/S0002-9149(97) 00920-X (Pubitemid 28099317)
12. Cardillo C., Campia U., Bryant M. B., Panza J. A., Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 2002 106 14 1783 1787 2-s2.0-0036789361 10.1161/01.CIR.0000032260.01569.64
13. Mather K. J., Mirzamohammadi B., Lteif A., Steinberg H. O., Baron A. D., Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes. Diabetes 2002 51 12 3517 3523 2-s2.0-0036895991 (Pubitemid 35403459)
14. Cardillo C., Campia U., Iantorno M., Panza J. A., Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients. Hypertension 2004 43 1 36 40 2-s2.0-0348049454 10.1161/01.HYP.0000103868.45064.81 (Pubitemid 38031908)
15. Lteif A., Vaishnava P., Baron A. D., Mather K. J., Endothelin limits insulin action in obese/insulin-resistant humans. Diabetes 2007 56 3 728 734 2-s2.0-33847404040 10.2337/db06-1406 (Pubitemid 46348477)
16. Douglas J. G., Bakris G. L., Epstein M., Ferdinand K. C., Ferrario C., Flack J. M., Jamerson K. A., Jones W. E., Haywood J., Maxey R., Ofili E. O., Saunders E., Schiffrin E. L., Sica D. A., Sowers J. R., Vidt D. G., Management of high blood pressure in African Americans: consensus statement of the hypertension in African Americans Working Group of the International Society on Hypertension in blacks. Archives of Internal Medicine 2003 163 5 525 541 2-s2.0-0037429639 10.1001/archinte.163.5.525 (Pubitemid 36314340)
17. Elijovich F., Laffer C. L., Participation of renal and circulating endothelin in salt-sensitive essential hypertension. Journal of Human Hypertension 2002 16 7 459 467 2-s2.0-0035984995 10.1038/sj.jhh.1001419 (Pubitemid 34790336)
18. Wenzel R. R., Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs 2005 65 2 29 39 2-s2.0-26944503427 (Pubitemid 41480578)
19. Parving H. H., Persson F., Lewis J. B., Lewis E. J., Hollenberg N. K., Aliskiren combined with losartan in type 2 diabetes and nephropathy. New England Journal of Medicine 2008 358 23 2433 2446 2-s2.0-44849114597 10.1056/NEJMoa0708379 (Pubitemid 351793017)
20. Kedzierski R. M., Yanagisawa M., Endothelin system: the double-edged sword in health and disease. Annual Review of Pharmacology and Toxicology 2001 41 851 876 2-s2.0-0035040924 10.1146/annurev.pharmtox.41.1.851 (Pubitemid 32385909)
21. Gurley S. B., Coffman T. M., The renin-angiotensin system and diabetic nephropathy. Seminars in Nephrology 2007 27 2 144 152 2-s2.0-34047247353 10.1016/j.semnephrol.2007.01.009 (Pubitemid 46550312)
22. Wilhelm S. M., Simonson M. S., Robinson A. V., Stowe N. T., Schulak J. A., Endothelin up-regulation and localization following renal ischemia and reperfusion. Kidney International 1999 55 3 1011 1018 2-s2.0-0011187848 10.1046/j.1523-1755.1999.0550031011.x (Pubitemid 29100713)
23. Hocher B., Thöne-Reineke C., Rohmeiss P., Schmager F., Slowinski T., Burst V., Siegmund F., Quertermous T., Bauer C., Neumayer H. H., Schleuning W. D., Theuring F., Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. Journal of Clinical Investigation 1997 99 6 1380 1389 2-s2.0-1842411863 (Pubitemid 27142776)
24. Simonson M. S., mss5@case.edu Ismail-Beigi F., Endothelin-1 increases collagen accumulation in renal mesangial cells by stimulating a chemokine and cytokine autocrine signaling loop. Journal of Biological Chemistry 2011 286 13 11003 11008 10.1074/jbc.M110.190793
25. Hocher B., Schwarz A., Reinbacher D., Jacobi J., Lun A., Priem F., Bauer C., Neumayer H. H., Raschack M., Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. Nephron 2001 87 2 161 169 2-s2.0-0035103048 10.1159/000045906 (Pubitemid 32215829)
26. Iglarz M., Schiffrin E. L., Role of endothelin-1 in hypertension. Current Hypertension Reports 2003 5 2 144 148 2-s2.0-0038351069 (Pubitemid 38898944)
27. Dhaun N., bean.dhaun@ed.ac.uk MacIntyre I. M., Kerr D., Melville V., Johnston N. R., Haughie S., Goddard J., Webb D. J., Selective endothelin-a receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 2011 57 4 772 779 10.1161/HYPERTENSIONAHA.110.167486
28. D'Uscio L. V., Moreau P., Shaw S., Takase H., Barton M., Lüscher T. F., Effects of chronic ET(A)-receptor blockade in angiotensin II-induced hypertension. Hypertension 1997 29 1 435 441 2-s2.0-0030636347 (Pubitemid 27074080)
29. D'Uscio L. V., Shaw S., Barton M., Lüscher T. F., Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase role of blood pressure and endothelial function. Hypertension 1998 31 6 1305 1310 2-s2.0-0031864167 (Pubitemid 28248832)
30. Emori T., Hirata Y., Ohta K., Kanno K., Eguchi S., Imai T., Shichiri M., Marumo F., Cellular mechanism of endothelin-1 release by angiotensin and vasopressin. Hypertension 1991 18 2 165 170 2-s2.0-0025739209
31. Herizi A., Jover B., Bouriquet N., Mimran A., Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade. Hypertension 1998 31 1 I 10 14 2-s2.0-0031941152 (Pubitemid 28124684)
32. Imai T., Hirata Y., Emori T., Yanagisawa M., Masaki T., Marumo F., Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension 1992 19 6 753 757 2-s2.0-0026566370
33. Rossi G. P., Sacchetto A., Cesari M., Pessina A. C., Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovascular Research 1999 43 2 300 307 2-s2.0-0033178254 10.1016/S0008-6363(99)00110-8 (Pubitemid 29356368)
34. Kawaguchi H., Sawa H., Yasuda H., Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells. Journal of Molecular and Cellular Cardiology 1990 22 8 839 842 2-s2.0-0025079136 10.1016/0022-2828(90)90115-I (Pubitemid 20281896)
35. Berk B. C., Fujiwara K., Lehoux S., ECM remodeling in hypertensive heart disease. Journal of Clinical Investigation 2007 117 3 568 575 2-s2.0-33847347313 10.1172/JCI31044 (Pubitemid 46348511)
36. Bohlender J., Gerbaulet S., Krämer J., Gross M., Kirchengast M., Dietz R., Synergistic effects of AT1 and ET(A) receptor blockade in a transgenic, angiotensin II-dependent, rat model. Hypertension 2000 35 4 992 997 2-s2.0-0034065004 (Pubitemid 30303963)
37. Gardiner S. M., March J. E., Kemp P. A., Mullins J. J., Bennett T., Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats. British Journal of Pharmacology 1995 116 4 2237 2244 2-s2.0-0028891914
38. 1receptor antagonist, MK-954. Journal of Cardiovascular Pharmacology 2000 36 5 S337 S341 2-s2.0-0033743313 10.1097/00005344-200000006-00001
39. Kohan D. E., donald.kohan@hsc.utah.edu Pritchett Y., Molitch M., Wen S., Garimella T., Audhya P., Andress D. L., Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. Journal of the American Society of Nephrology 2011 22 4 763 772 10.1681/ASN.2010080869
40. Joshi D., Gupta R., Dubey A., Shiwalkar A., Pathak P., Gupta R. C., Chauthaiwale V., Dutt C., TRC4186, a novel AGE-breaker, improves diabetic cardiomyopathy and nephropathy in Ob-ZSF1 model of type 2 diabetes. Journal of Cardiovascular Pharmacology 2009 54 1 72 81 2-s2.0-68249149199 10.1097/FJC.0b013e3181ac3a34
41. Cingolani O. H., Yang X. P., Cavasin M. A., Carretero O. A., Increased systolic performance with diastolic dysfunction in adult spontaneously hypertensive rats. Hypertension 2003 41 2 249 254 2-s2.0-0037317781 10.1161/01.HYP.0000052832.96564.0B (Pubitemid 36204897)
42. Pacher P., Liaudet L., Bai P., Mabley J. G., Kaminski P. M., Virág L., Deb A., Szabó É.., Ungvári Z., Wolin M. S., Groves J. T., Szabó C., Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 2003 107 6 896 904 2-s2.0-0037448784 10.1161/01.CIR.0000048192.52098.DD (Pubitemid 36241050)
43. Pacher P., Mabley J. G., Liaudet L., Evgenov O. V., Marton A., Haskó G., Kollai M., Szabó C., Left ventricular pressure-volume relationship in a rat model of advanced aging-associated heart failure. American Journal of Physiology 2004 287 5 H2132 H2137 2-s2.0-7244230974 10.1152/ajpheart.00405.2004 (Pubitemid 39430753)
44. Westerhof B. E., Guelen I., Westerhof N., Karemaker J. M., Avolio A., Quantification of wave reflection in the human aorta from pressure alone: a proof of principle. Hypertension 2006 48 4 595 601 2-s2.0-33750590779 10.1161/01.HYP.0000238330.08894.17 (Pubitemid 44843861)
45. Luna L. G., Histologic Staining Methods of the Armed Forces Institute of Pathology 1998 3rd Mcgraw-Hill
46. Tofovic S. P., Kusaka H., Kost C. K., Bastacky S., Renal function and structure in diabetic, hypertensive, obese ZDFxSHHF- hybrid rats. Renal Failure 2000 22 4 387 406 2-s2.0-0033936107 10.1081/JDI-100100882 (Pubitemid 30441636)
47. Grassi G., Schiffrin E. L., Media-to-lumen ratio as predictor of renal abnormalities in hypertension: new findings, new questions. Journal of Hypertension 2010 28 9 1811 1813 2-s2.0-77955794343 10.1097/HJH.0b013e32833d7fed
48. Prabhakar S., Starnes J., Shi S., Lonis B., Tran R., Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. Journal of the American Society of Nephrology 2007 18 11 2945 2952 2-s2.0-35848956112 10.1681/ASN.2006080895 (Pubitemid 350058402)
49. Schmieder R. E., Klingbeil A. U., Fleischmann E. H., Veelken R., Delles C., Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. Journal of the American Society of Nephrology 2005 16 10 3038 3045 2-s2.0-33645060064 10.1681/ASN.2005020138 (Pubitemid 44743501)
50. Peppa-Patrikiou M., Dracopoulou M., Dacou-Voutetakis C., Urinary endothelin in adolescents and young adults with insulin-dependent diabetes mellitus: relation to urinary albumin, blood pressure, and other factors. Metabolism 1998 47 11 1408 1412 2-s2.0-0031724557 (Pubitemid 28523477)
51. Viswanathan V., Prevention of diabetic nephropathy: a diabetologist's perspective. Indian Journal of Nephrology 2004 14 157 162
52. Qi M. Y., Liu H. R., Dai D. Z., Li N., Dai Y., Total triterpene acids, active ingredients from Fructus Corni, attenuate diabetic cardiomyopathy by normalizing ET pathway and expression of FKBP12.6 and SERCA2a in streptozotocin-rats. Journal of Pharmacy and Pharmacology 2008 60 12 1687 1694 2-s2.0-56849126613 10.1211/jpp/60.12.0016
53. He H., Liu Q., Shi M., Zeng X., Yang J., Wu L., Li L., Cardioprotective effects of hydroxysafflor yellow a on diabetic cardiac insufficiency attributed to up-regulation of the expression of intracellular calcium handling proteins of sarcoplasmic reticulum in rats. Phytotherapy Research 2008 22 8 1107 1114 2-s2.0-50149106755 10.1002/ptr.2468
54. Qi M. Y., Xia H. J., Dai D. Z., Dai Y., A novel endothelin receptor antagonist CPU0213 improves diabetic cardiac insufficiency attributed to up-regulation of the expression of FKBP12.6, SERCA2a, and PLB in rats. Journal of Cardiovascular Pharmacology 2006 47 6 729 735 2-s2.0-33748099338 10.1097/01.fjc.0000211765.52012.aa (Pubitemid 44305245)
55. Amann K., Münter K., Wessels S., Wagner J., Balajew V., Hergenröder S., Mall G., Ritz E., Endothelin a receptor blockade prevents capillary/myocyte mismatch in the heart of uremic animals. Journal of the American Society of Nephrology 2000 11 9 1702 1711 2-s2.0-0033844691
56. Gagliardini E., Corna D., Zoja C., Sangalli F., Carrara F., Rossi M., Conti S., Rottoli D., Longaretti L., Remuzzi A., Remuzzi G., Benigni A., Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. American Journal of Physiology 2009 297 5 F1448 F1456 2-s2.0-70350704811 10.1152/ajprenal.00340.2009
57. Macconi D., Ghilardi M., Bonassi M. E., Mohamed E. I., Abbate M., Colombi F., Remuzzi G., Remuzzi A., Effect of angiotensin-converting enzyme inhibition on glomerular basement membrane permeability and distribution of zonula occludens-1 in MWF rats. Journal of the American Society of Nephrology 2000 11 3 477 489 2-s2.0-0034094361 (Pubitemid 30115077)
58. Ruggenenti P., Mosconi L., Vendramin G., ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome. American Journal of Kidney Diseases 2000 35 3 381 391
59. Sorokin A., Kohan D. E., Physiology and pathology of endothelin-1 in renal mesangium. American Journal of Physiology 2003 285 4 F579 F589 2-s2.0-0141813519 (Pubitemid 37140242)
60. Amann K., Simonaviciene A., Medwedewa T., Koch A., Orth S., Gross M. L., Haas C., Kuhlmann A., Linz W., Schölkens B., Ritz E., Blood pressure-independent additive effects of pharmacologic blockade of the renin-angiotensin and endothelin systems on progression in a low-renin model of renal damage. Journal of the American Society of Nephrology 2001 12 12 2572 2584 2-s2.0-0035204325 (Pubitemid 33115403)
61. Saleh M. A., Boesen E. I., Pollock J. S., Savin V. J., Pollock D. M., Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat. Hypertension 2010 56 5 942 949 2-s2.0-78149277201 10.1161/HYPERTENSIONAHA.110.156570
62. Zoja C., Liu X. H., Abbate M., Coma D., Schiffrin E. L., Remuzzi G., Benigni A., Angiotensin II blockade limits tubular protein overreabsorption and the consequent upregulation of endothelin 1 gene in experimental membranous nephropathy. Experimental Nephrology 1998 6 2 121 131 2-s2.0-0031952293 (Pubitemid 28140993)
63. Remuzzi G., Bertani T., Pathophysiology of progressive nephropathies. New England Journal of Medicine 1998 339 20 1448 1456 2-s2.0-0032512094 10.1056/NEJM199811123392007 (Pubitemid 28516069)
64. Lehrke I., Waldherr R., Ritz E., Gene expression of the endothelin system in renal biopsies of proteinuric patients: effect of angiotensin converting enzyme. Journal of the American Society of Nephrology 1999 10 80
65. Peterson R. G., Anders A. F. S., Elazar S., The Zucker diabetic fatty rat. Animal Models of Diabetes: A Primer 2000 Amsterdam, The Netherlands Harwood Academic 109 127
66. Dixon R., Brunskill N. J., Activation of mitogenic pathways by albumin in kidney proximal tubule epithelial cells: implications for the pathophysiology of proteinuric states. Journal of the American Society of Nephrology 1999 10 7 1487 1497 2-s2.0-0033028468 (Pubitemid 29297523)
67. Baines R. J., Brunskill N. J., Tubular toxicity of proteinuria. Nature Reviews Nephrology 2011 7 3 177 180 2-s2.0-78649924568 10.1038/nrneph.2010.174
68. Yusuf S., Sleight P., Pogue J., Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New England Journal of Medicine 2000 342 3 145 153 10.1056/NEJM200001203420301 (Pubitemid 30051645)
69. Hileeto D., Cukiernik M., Mukherjee S., Evans T., Barbin Y., Downey D., Karmazyn M., Chakrabarti S., Contributions of endothelin-1 and sodium hydrogen exchanger-1 in the diabetic myocardium. Diabetes/Metabolism Research and Reviews 2002 18 5 386 394 2-s2.0-0036709959 10.1002/dmrr.322 (Pubitemid 35256595)
70. Witte K., Reitenbach I., Stolpe K., Schilling L., Kirchengast M., Lemmer B., Effects of the endothelin A receptor antagonist darusentan on blood pressure and vascular contractility in type 2 diabetic Goto-Kakizaki rats. Journal of Cardiovascular Pharmacology 2003 41 6 890 896 2-s2.0-0038457616 10.1097/00005344-200306000-00009 (Pubitemid 36706136)
71. Verma S., Arikawa E., McNeill J. H., Long-term endothelin receptor blockade improves cardiovascular function in diabetes. American Journal of Hypertension 2001 14 7 I 679 687 2-s2.0-0034952322 10.1016/S0895-7061(01)01302-4 (Pubitemid 32612533)
72. Dhein S., Hochreuther S., Spring C. A. D., Bollig K., Hufnagel C., Raschack M., Long-term effects of the endothelin(A) receptor antagonist LU 135252 and the angiotensin-converting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model. Journal of Pharmacology and Experimental Therapeutics 2000 293 2 351 359 2-s2.0-0034057291 (Pubitemid 30244081)
73. Neal B., MacMahon S., Chapman N., Blood pressure lowering treatment trialists collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood pressure- lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000 356 9246 1955 1964